Clinical trial • Phase III • Oncology
Clinical trial in Small cell lung cancer|Small cell lung cancer, metastatic|Small cell lung cancer, limited stage
Phase III trial for Small cell lung cancer|Small cell lung cancer, metastatic|Small cell lung cancer, limited stage. 15 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Small cell lung cancer|Small cell lung cancer, metastatic|Small cell lung cancer, limited stage
- Trial Stage
- Phase III
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 31-01-2025
- First CTIS Authorization Date
- 06-05-2025
Trial design
Phase III trial across 3 sites in France.
- Target Sample Size
- 15
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 43
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 15
France
- Earliest CTIS Part Ii Submission Date
- 28-03-2025
- Latest Decision Or Authorization Date
- 12-03-2026
- Processing Time Days
- 349
- Number Of Sites
- 3
- Number Of Participants
- 15
Sites
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Nuclear Medicine
- Principal Investigator Name
- Marie LACOMBE
- Principal Investigator Email
- marie.lacombe@ico.unicancer.fr
- Contact Person Name
- Marie LACOMBE
- Contact Person Email
- marie.lacombe@ico.unicancer.fr
- Site Name
- Centre Hospitalier Regional D'Angers
- Department Name
- Nuclear Medicine
- Principal Investigator Name
- Clément BOURON
- Principal Investigator Email
- clbouron@chu-angers.fr
- Contact Person Name
- Clément BOURON
- Contact Person Email
- clbouron@chu-angers.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Nuclear Medicine
- Principal Investigator Name
- Marie LACOMBE
- Principal Investigator Email
- marie.lacombe@ico.unicancer.fr
- Contact Person Name
- Marie LACOMBE
- Contact Person Email
- marie.lacombe@ico.unicancer.fr
Sponsor
Primary sponsor
- Full Name
- Institut De Cancerologie De L Ouest
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)